Literature DB >> 17018687

Consequences of combining cystic fibrosis- and non-cystic fibrosis-derived Pseudomonas aeruginosa antibiotic susceptibility results in hospital antibiograms.

John A Bosso1, Patrick D Mauldin, Lisa L Steed.   

Abstract

BACKGROUND: In preparing hospital antibiograms for individual organisms and antibiotics, laboratories often combine susceptibility data for isolates from a variety of sources and patient types. If results from patients with known resistance patterns that vary from normal are included, the overall susceptibility value for the institution could be misleadingly skewed.
OBJECTIVE: To assess the degree of bias introduced into a hospital antibiogram by combining cystic fibrosis (CF) and non-CF isolates of Pseudomonas aeruginosa to produce one hospital-wide percent susceptible figure for each tested antibiotic.
METHODS: A retrospective analysis was conducted of an academic, tertiary care medical center's microbiology database. We examined quarterly and annual susceptibility data from 2004, comparing non-CF data with combined susceptibility data for 10 antibiotics within each quarter, as well as those reported in the annual antibiogram. Differences were assessed for statistical significance using chi(2) testing with Bonferroni correction.
RESULTS: Large differences were observed between non-CF and combined percent susceptible data in the 4 quarters (aminoglycosides 3% vs 20%, fluoroquinolones 2% vs 18%, respectively) and when comparing annual non-CF (n = 191) with annual combined (n = 266) data. With the annual figures, these differences were frequently statistically significant (70% vs 58%, 91% vs 83%, 85% vs 70%, and 72% vs 60% for gentamicin, tobramycin, amikacin, and gatifloxacin/levofloxacin, respectively; all p< or =0.01).
CONCLUSIONS: Combining CF and non-CF P. aeruginosa susceptibility into one percent susceptibility value for all isolates may produce figures that underestimate the activity of some antibiotic classes against non-CF isolates. Clinicians may make less than optimal empiric antibiotic selection choices based on such data.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17018687     DOI: 10.1345/aph.1H377

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  6 in total

1.  Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America.

Authors:  Tamar F Barlam; Sara E Cosgrove; Lilian M Abbo; Conan MacDougall; Audrey N Schuetz; Edward J Septimus; Arjun Srinivasan; Timothy H Dellit; Yngve T Falck-Ytter; Neil O Fishman; Cindy W Hamilton; Timothy C Jenkins; Pamela A Lipsett; Preeti N Malani; Larissa S May; Gregory J Moran; Melinda M Neuhauser; Jason G Newland; Christopher A Ohl; Matthew H Samore; Susan K Seo; Kavita K Trivedi
Journal:  Clin Infect Dis       Date:  2016-04-13       Impact factor: 9.079

2.  Variation in antibiotic susceptibility of uropathogens by age among ambulatory pediatric patients.

Authors:  Jessina C McGregor; Yennie Quach; David T Bearden; David H Smith; Susan E Sharp; Judith A Guzman-Cottrill
Journal:  J Pediatr Nurs       Date:  2013-09-30       Impact factor: 2.145

3.  Comparison of Hospitalwide and Custom Antibiograms for Clinical Isolates of Pseudomonas aeruginosa.

Authors:  John A Bosso; Adam Sieg; Patrick D Mauldin
Journal:  Hosp Pharm       Date:  2013-04

4.  Linking antimicrobial resistance surveillance to antibiotic policy in healthcare settings: the COMBACTE-Magnet EPI-Net COACH project.

Authors:  Maria Diletta Pezzani; Fulvia Mazzaferri; Monica Compri; Liliana Galia; Nico T Mutters; Gunnar Kahlmeter; Theoklis E Zaoutis; Mitchell J Schwaber; Jesús Rodríguez-Baño; Stephan Harbarth; Evelina Tacconelli
Journal:  J Antimicrob Chemother       Date:  2020-12-06       Impact factor: 5.790

5.  Lessons Learned from Surveillance of Antimicrobial Susceptibilities of Pseudomonas aeruginosa at a Large Academic Medical Center.

Authors:  Brett H Heintz; Jenana Halilovic
Journal:  Pharmaceuticals (Basel)       Date:  2010-04-01

6.  Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data--The Influence of Different Parameters in a Routine Clinical Microbiology Laboratory.

Authors:  Rebekka Kohlmann; Sören G Gatermann
Journal:  PLoS One       Date:  2016-01-27       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.